Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

The Lancet Oncology
Martin FassnachtGary D Hammer

Abstract

Adrenocortical carcinoma is a rare, aggressive cancer for which few treatment options are available. Linsitinib (OSI-906) is a potent, oral small molecule inhibitor of both IGF-1R and the insulin receptor, which has shown acceptable tolerability and preliminary evidence of anti-tumour activity. We assessed linsitinib against placebo to investigate efficacy in patients with advanced adrenocortical carcinoma. In this international, double-blind, placebo-controlled phase 3 study, adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical sites in nine countries. Patients were randomly assigned (2:1) twice-daily 150 mg oral linsitinib or placebo via a web-based, centralised randomisation system and stratified according to previous systemic cytotoxic chemotherapy for adrenocortical carcinoma, Eastern Cooperative Oncology Group performance status, and use of one or more oral antihyperglycaemic therapy at randomisation. Allocation was concealed by blinded block size and permuted block randomisation. The primary endpoint was overall survival, calculated from date of randomisation until death from any cause. The primary analysis was done in the intention-to-treat popul...Continue Reading

References

Jan 28, 2003·The American Journal of Pathology·Thomas J GiordanoSamir M Hanash
Jun 8, 2007·The New England Journal of Medicine·Massimo TerzoloAlfredo Berruti
Oct 16, 2008·The Journal of Clinical Endocrinology and Metabolism·Ferdous M BarlaskarGary D Hammer
Nov 27, 2008·Journal of Mammary Gland Biology and Neoplasia·Quanri Jin, Francisco J Esteva
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 14, 2010·Molecular Cancer·J Rafael SierraSilvia Giordano
Jul 6, 2010·Biochemical Pharmacology·Steven A Rosenzweig, Hanudatta S Atreya
May 2, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marco VolanteAlfredo Berruti
Jul 18, 2012·The American Journal of Pathology·Joanne H HeatonGary D Hammer
Jul 28, 2012·The Journal of Clinical Endocrinology and Metabolism·Matthias KroissMartin Fassnacht
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BerrutiUNKNOWN ESMO Guidelines Working Group
Oct 2, 2013·The Journal of Clinical Endocrinology and Metabolism·Martin FassnachtBruno Allolio
Oct 11, 2013·Molecular Cancer Therapeutics·Adam PavlicekJames G Christensen
Dec 5, 2013·The Journal of Clinical Endocrinology and Metabolism·Tobias ElseGary D Hammer
Jan 16, 2014·Endocrine Reviews·Tobias ElseGary D Hammer
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robin L JonesCraig P Carden
Sep 13, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Igor PuzanovT R Jeffry Evans

❮ Previous
Next ❯

Citations

Jan 16, 2016·Molecular and Cellular Endocrinology·Constanze HantelFelix Beuschlein
Jan 23, 2016·Frontiers in Endocrinology·Helen Louise Robbins, Angela Hague
May 27, 2014·The Surgical Clinics of North America·Ryaz ChagparEren Berber
Jan 17, 2016·BMC Medical Genetics·Natália BertoniPatricia P Reis
Jan 13, 2016·Clinical and Translational Medicine·Kimberly J BusseyMichael J Demeure
Jul 15, 2015·Journal of Endocrinological Investigation·A StiglianoM Terzolo
Dec 19, 2015·Molecular and Cellular Endocrinology·Kaitlin J BashamGary D Hammer
Mar 11, 2016·Hormones & Cancer·Matthias KroissUNKNOWN German Adrenocortical Carcinoma Study Group
Mar 21, 2016·Molecular and Cellular Endocrinology·Felix BeuschleinConstanze Hantel
Aug 12, 2015·Endocrine-related Cancer·T M A KerkhofsH R Haak
Dec 8, 2015·International Journal of Cancer. Journal International Du Cancer·Barbara AltieriGiovanna Muscogiuri
Mar 22, 2015·The Lancet Oncology·Lawrence S Kirschner
Aug 2, 2015·Cancer Letters·Isabel HeideggerHelmut Klocker
Jun 4, 2015·Endocrinology and Metabolism Clinics of North America·Eric Baudin, UNKNOWN Endocrine Tumor Board of Gustave Roussy
May 18, 2016·Endocrine-related Cancer·Régia Caroline Peixoto LiraCarlos Alberto Scrideli
Oct 18, 2016·International Journal of Cancer. Journal International Du Cancer·Francesco SclafaniDavid J Watkins
Oct 26, 2016·Biological Reviews of the Cambridge Philosophical Society·Judy R van BeijnumArjan W Griffioen
Dec 18, 2016·Journal of Cellular Biochemistry·Jaqueline Cristina FernandesFabiola Traina
Apr 4, 2017·Oncogene·M Batisse-LignierA-M Lefrançois-Martinez
Mar 10, 2017·Current Opinion in Endocrinology, Diabetes, and Obesity·Jeena Varghese, Mouhammed Amir Habra
Apr 13, 2017·Endocrine-related Cancer·Anna AngelousiAshley Grossman
Apr 4, 2017·Endocrinology·Giovanna MuscogiuriAnnamaria Colao
Feb 17, 2018·The Journal of Clinical Endocrinology and Metabolism·Felix MegerleUNKNOWN German ACC Study Group
Apr 13, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Haslam, V Prasad
Dec 24, 2017·Journal of Molecular Endocrinology·Caterina Mancarella, Katia Scotlandi
Jan 31, 2018·Journal of Molecular Endocrinology·Douglas Yee
May 24, 2018·Endocrinology·Katja Kiseljak-VassiliadesMargaret E Wierman
May 19, 2018·European Journal of Endocrinology·Sofia S PereiraDuarte Pignatelli
Aug 18, 2018·Expert Review of Anticancer Therapy·Soraya PuglisiMassimo Terzolo
Nov 17, 2017·Endocrine-related Cancer·Enzo Lalli, Michaela Luconi
Jan 27, 2018·Endocrine-related Cancer·Katja Kiseljak-VassiliadesMargaret E Wierman
Aug 17, 2018·The Journal of Clinical Endocrinology and Metabolism·Juliane LippertCristina L Ronchi
Jul 3, 2018·Minerva endocrinologica·Barbara AltieriAntongiulio Faggiano
May 29, 2018·Minerva endocrinologica·Jacopo Manso, Raffaele Pezzani
Aug 4, 2018·Journal of Molecular Endocrinology·James F H Pittaway, Leonardo Guasti
Nov 27, 2018·The Journal of Endocrinology·Manuel D GaheteRaul M Luque
Nov 8, 2018·Journal of the Endocrine Society·Dipika R MohanGary D Hammer
Oct 4, 2017·Endocrine Reviews·Antonino BelfioreRiccardo Vigneri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.